Skip navigation
Home
News
Products
about IR-World
Team
Customers
Partner
Contact
DE
EN
Communicators
are winners!
Text der Meldung
More News
20.01.2022
Sernova Announces Peer Reviewed Publication Demonstrating Safety and Efficacy of a Novel Cell Pouch Cell Therapy Approach for Treatment of Severe Hemophilia A
10.01.2022
The Principal Investigator in Sernova’s Type 1 Diabetes (T1D) Trial Confirms Patients with a History of Hypoglycemia Unawareness Are Now Insulin Independent
14.12.2021
Sernova Appoints Christopher Barnes as Vice President, Investor Relations & Grants Options/DSUs
02.12.2021
Sernova Announces Appointment of Executive Chair to Complement its Management Team
01.10.2021
Sernova: The Ultimate Combination of Two Proven Technologies as Potential Functional Cure for Type 1 Diabetes and Other Chronic Diseases
29.09.2021
Sernova Engages New York-Based LifeSci Advisors as US Investor Relations Partner
16.09.2021
Sernova Signs Collaboration Agreement to Advance Conformal Coated Immune Protected Therapeutic Cells for Diabetes with the University of Miami
09.08.2021
Sernova to Present Corporate Update at Canaccord Genuity’s 41st Annual Growth Conference
05.07.2021
Sernova Announces 2021 Annual Meeting Results: Shareholders Approve Resolutions with Overwhelming Majority
30.06.2021
Industry Veteran Frank Shannon Joins Sernova as VP Clinical Development and Regulatory Affairs
First
Previous
2
3
4
5
6
7
8
Next
Last